Yang Xin Yuan

Dr. Yang Xin Yuan


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
ZWZhen Wang
Zhen Wang
YWYueling Wang
Yueling Wang
TYTing Yang
Ting Yang
JLJing Li
Jing Li
YYYang Xin Yuan
Yang Xin Yuan
Young female patients who receive chemotherapy frequently face premature ovarian failure (POF). The therapeutic potential of stem cells in these patients has been explored in stem cells derived from different sources. However, many of these types of stem cells are either difficult to obtain or obtaining them involves invasive procedures. Here, we show that menstrual-derived stem cells (MenSCs) are easy to access and exhibit mesenchymal stem cell-like properties. MenSCs are therefore a novel source of stem cells that can be used for tissue repair. The aim of this study was to explore the reparative capacity and the mechanism underlying the activities of MenSCs. POF mouse models were established by 7 consecutive days of intraperitoneal injection of cisplatin, and then MenSCs or MenSC-derived conditioned media (CM) were infused via the tail vein. The ovaries were excised after either 7 or 21 days of treatment and the follicles were counted and categorized. Apoptosis of granulosa cells was observed by terminal deoxynucleotidyl transferase mediated dUTP nick end labelling staining. Ovarian function was evaluated by monitoring serum sex hormone levels. Furthermore, MenSC tracking, Q-PCR, and small interfering RNA transfection were used to reveal the inner mechanism of repair. MenSC transplantation could improve the ovarian microenvironment by reducing apoptosis in granulosa cells and the fibrosis of ovarian interstitium, which contributes to increase the follicular numbers and return sex hormone levels to normal values. Meanwhile, the transplanted MenSCs directively migrate to ovarian interstitium to play a role in repair rather than differentiate to oocytes directly. Additionally, MenSCs and CM derived from these cells exerted protective effects on damaged ovaries partially by secreting FGF2. MenSCs repair ovarian injury, improve ovarian function, and stimulate regeneration, suggesting that transplantation of MenSCs may provide an effective and novel method for treating POF.

6 December 2022 in Pathology - Research and Practice
Verified
Journal Article
Closed access
QJQingge Jia
Qingge Jia
JSJunyang Song
Junyang Song
TXTianqi Xu
Tianqi Xu
JLJin Liu
Jin Liu
JCJia Chai
Jia Chai
YYYang Xin Yuan
Yang Xin Yuan

8 March 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
ZWZhen Wang
Zhen Wang
YWYueling Wang
Yueling Wang
TYTing Yang
Ting Yang
JLJing Li
Jing Li
YYYang Xin Yuan
Yang Xin Yuan

1 July 2025 in Pathology - Research and Practice
Verified
Journal Article
Closed access
QJQingge Jia
Qingge Jia
MLMingyang Li
Mingyang Li
YMYannan Ma
Yannan Ma
JLJin Liu
Jin Liu
QZQin Zhang
Qin Zhang
YYYang Xin Yuan
Yang Xin Yuan

1 July 2026 in Pathology - Research and Practice
Verified
Journal Article
Closed access
QJQingge Jia
Qingge Jia
JLJin Liu
Jin Liu
TXTianqi Xu
Tianqi Xu
PZPusong Zhao
Pusong Zhao
PWPeng Wang
Peng Wang
YYYang Xin Yuan
Yang Xin Yuan

26 July 2026 in Neoplasia
Verified
Journal Article
Open access
QJQingge Jia
Qingge Jia
MLMingyang Li
Mingyang Li
JLJin Liu
Jin Liu
TXTianqi Xu
Tianqi Xu
JXJunpeng Xu
Junpeng Xu
YYYang Xin Yuan
Yang Xin Yuan
Cervical squamous cell carcinoma (CESC) is frequently complicated by cisplatin (CDDP) resistance, which is a primary cause of treatment failure and poor prognosis. Here, we identified a CLCF1-ZIC5-CNTFR feedback loop that contributes to CDDP resistance in CESC. We found that ZIC5 was significantly upregulated in CDDP-resistant CESC and correlated with worse overall survival. Functionally, ZIC5 promoted CDDP resistance, in part by enhancing properties associated with cancer stem cells (CSCs) through the transcriptional activation of CNTFR. CLCF1, the ligand for CNTFR, was found to induce ZIC5 expression via STAT3 signaling, thereby forming a CLCF1-ZIC5-CNTFR positive feedback loop. Targeting CNTFR with a neutralizing antibody disrupted this regulatory circuit, leading to a reversal of CDDP resistance and suppression of CSC-associated phenotypes in vitro. Furthermore, combining an anti-CNTFR antibody with CDDP resulted in enhanced antitumor effects in patient-derived xenograft (PDX) and organoid (PDO) models. In summary, our findings suggest that the CLCF1-ZIC5-CNTFR positive feedback loop promotes CDDP resistance in CESC, potentially by sustaining CSC properties. Targeting this pathway, particularly CNTFR, may represent a potential therapeutic strategy for patients with CDDP-resistant CESC.